Skip to main content
Clinical Trials/NCT00390065
NCT00390065
Completed
Phase 4

Follow-Up at 6 Years of a Cohort of Children Born Very Prematurely With Respiratory and Neurodevelopmental Impact of Early Treatment With Inhaled Nitric Oxide

Maternite Regionale Universitaire2 sites in 1 country108 target enrollmentOctober 2006
ConditionsPremature Birth
InterventionsNitric Oxide

Overview

Phase
Phase 4
Intervention
Nitric Oxide
Conditions
Premature Birth
Sponsor
Maternite Regionale Universitaire
Enrollment
108
Locations
2
Primary Endpoint
Pulmonary Function testing
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

Utilization of nitric oxide (NO) therapy has been related to a trend towards short term improvement in very premature infants. A two year follow-up of children treated soon after birth with NO in the neonatal period, suggests that a significant improvement in neurodevelopmental outcome might occur. This study aims to evaluate follow-up at 6 years, in respiratory and neurodevelopmental outcome, of children born very prematurely, some of them having been treated with nitric oxide in the neonatal period.

Detailed Description

Utilization of nitric oxide therapy in the neonatal period has been related to a trend towards short term improvements in respiratory and neurological outcome at 28 days postnatal age or 36 weeks postconceptional age. A two year follow-up in children treated soon after birth with NO in the neonatal period, suggests that a significant improvement in neurodevelopmental outcome might occur. No long term evaluation on respiratory outcome has yet been done. This study aims to evaluate respiratory and neurodevelopmental outcome at 6 years of age in children born very prematurely, some of them having had Nitric Oxide as a rescue treatment for respiratory distress syndrome.

Registry
clinicaltrials.gov
Start Date
October 2006
End Date
June 2009
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Maternite Regionale Universitaire
Responsible Party
Principal Investigator
Principal Investigator

Jean Michel Hascoet

Professor - Head of Division

Maternite Regionale Universitaire

Eligibility Criteria

Inclusion Criteria

  • All infants included at birth in a randomized controlled trial using early nitric oxide therapy

Exclusion Criteria

  • Parental refusal

Arms & Interventions

Study group

Hypoxemic Respiratory Failure treated by Nitric Oxide;

Intervention: Nitric Oxide

Control

Hypoxemic Respiratory Failure control (Placebo);

Intervention: Nitric Oxide

Outcomes

Primary Outcomes

Pulmonary Function testing

Time Frame: at 7 years postnatal age

Secondary Outcomes

  • Neurodevelopmental and Cognitive outcomes(at 7 years of age)

Study Sites (2)

Loading locations...

Similar Trials